Filana Therapeutics Inc

Filana Therapeutics Inc has a strong liquidity position, with a current ratio of 4.07 and cash and equivalents amounting to $207.29 million, indicating a robust ability to meet short-term obligations. The company's debt-to-equity ratio is 0.0, reflecting no long-term debt and a capital structure that is entirely equity-funded. This liquidity position is further supported by a free cash flow of $6.43 million, despite an operating cash flow of -$37.37 million.

In terms of profitability, the company reported a net income of $6.16 million and an operating income of -$61.40 million, resulting in a return on equity of 3.26% and a return on assets of 2.53%. These figures suggest that while the company is generating positive net income, it is experiencing significant operating losses, which may impact its long-term profitability and sustainability.

Filana Therapeutics Inc's revenue concentration and geographic exposure are not explicitly detailed in the available data, making it difficult to assess the company's segment and geographic diversification. However, the absence of detailed segment data implies that the company's operations may be concentrated in a single business line or geographic region, which could pose concentration risks.

The company's growth trajectory is not clearly defined in the available data, as there are no specific numeric deltas or revenue history provided to indicate the direction of growth for the current or next fiscal year. The lack of detailed growth metrics makes it challenging to assess the company's future performance and expansion potential.

Risk factors for Filana Therapeutics Inc include a low liquidity risk, as indicated by the strong current ratio and substantial cash reserves. However, the company's dilution potential could not be assessed due to missing basic and diluted share counts. This uncertainty may affect investor confidence and the company's ability to raise capital without diluting existing shareholders.

Recent events and filings for Filana Therapeutics Inc are not detailed in the available data, which limits the ability to provide insights into the company's recent strategic moves or operational developments. The absence of recent events data suggests that the company may not have disclosed significant developments in the near term.

Filana Therapeutics Inc (FLNA.O) has recorded notable additions to its shareholder base, marking the first analysis for this ticker with no prior basis for delta computation. The most significant recent activity involves an investor (ID 465) acquiring 2,375,589 shares valued at approximately $4.7 million as of December 31, 2025. This position represents a portfolio weight of roughly 0.000068%, indicating a focused but relatively small allocation within the investor's broader holdings. Additional notable holder changes were detected for earlier periods, including an acquisition of 3,219,649 shares valued at $39.76 million by investor ID 466 as of June 30, 2024. Another investor (ID 497) added 165,514 shares valued at $0.39 million as of December 31, 2024. These transactions highlight a pattern of institutional or significant investor interest across multiple reporting periods, despite the lack of prior comparative data for this specific ticker. The company currently maintains a shareholder base comprising 21 top holders, yet it lacks coverage from financial analysts and is not included in any major indices. With zero officers listed in the current dataset, the governance structure appears minimal or unreported in this context. The absence of analyst ratings and index membership suggests that Filana Therapeutics remains a niche or early-stage investment vehicle with limited mainstream financial scrutiny. These holder changes matter as they provide the initial visibility into capital flows for Filana Therapeutics. The accumulation of shares by distinct investors, particularly the substantial $39.76 million position from mid-2024, suggests underlying confidence in the company's prospects despite the lack of public analyst consensus. For investors, these data points serve as the foundational metrics for assessing liquidity and institutional interest in the absence of traditional financial coverage.